Pharma News

Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congen...

Building on the CRISPR gene-editing system, MIT researchers have designed a new tool that can snip out faulty genes and replace them with new ones, in a safer and more efficient way. ...

South African bio-pharmaceutical firm Biovac and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing ...

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments.

Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accele...

The FDA has approved Jazz Pharmaceuticals’ supplemental Biologics License Application (sBLA) for an additional dosing schedule for Rylaze (asparaginase erwinia chrysanthemi recombinant) to treat...

The FDA has accepted Apellis Pharmaceuticals’ major amendment to its new drug application (NDA) for pegcetacoplan for the treatment of patients with geographic atrophy secondary to age-related m...

Nona will offer access to its technologies and antibody generation services to Dragonfly for the targets chosen by the latter.

The FDA has granted Breakthrough Therapy status for Iveric Bio’s Zimura (avacincaptad pegol)  for geographic atrophy secondary to age-related macular degeneration (AMD) which leads to progre...

While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioScie...

ACU193, an antibody developed based on its selectivity for soluble amyloid-ß oligomers, is currently being assessed in a phase 1 trial, with a potential phase 2/3 trial in the near future. ...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatmen...